๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Edinburgh
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Edinburgh

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:26 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 136 Manchester 74 Cambridge 64 Edinburgh 34 Glasgow 34
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca34 Merck Sharp & Dohme LLC15 Janssen Research & Development, LLC13 AbbVie10 Hoffmann-La Roche9 Clear sponsor filter
Site city
London136 Manchester74 Cambridge64 Edinburgh34 Glasgow34
All 136 cities
Target enrolment
to
34 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
1,200
Aberdeen, Addlestone, Banbury, Bristol, Edinburgh, Hounslow, Penzance, Poole
2026-07-06
Recruiting
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978Newly Diagnosed Multiple Myeloma
AstraZeneca
Phase 3
750
Edinburgh, London, Manchester
2026-06-26
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bristol, Cottingham, Edinburgh, Exeter, Liverpool, London
2026-06-11
Recruiting
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
NCT07509151Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
AstraZeneca
Phase 3
420
Edinburgh, Hampshire, Leeds, London, Manchester, Nottingham, Oxford, Sutton
2026-05-05
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
AstraZeneca
Phase 1
27
Edinburgh, London
2026-01-09
Recruiting
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
NCT07155226Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
AstraZeneca
Phase 1/2
84
Edinburgh, London, Manchester, Newcastle
2026-01-09
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
AstraZeneca
Phase 3
1,100
Barrow in Furness, Birmingham, Cambridge, Canterbury, Cardiff, Edinburgh, Greater London, London
2025-12-29
Recruiting
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization
AstraZeneca
Phase 2
435
Belfast, Birmingham, Brighton, Cambridge, Dundee, Edinburgh, Exeter, Liverpool
2025-11-06
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
AstraZeneca
Phase 3
700
Aberdeen, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Greater London, Guildford
2025-08-06
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-18
Recruiting
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
NCT05663515Pancreatic Cancer
AstraZeneca
Observational
24,000
Edinburgh, London
2024-09-30
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Edinburgh, London, Wolverhampton
2024-06-20
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
4,300
Brighton, Burton-on-Trent, Cambridge, Derby, Edinburgh, Guildford, Ipswich, Keighley
2023-03-31
Recruiting
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229Gastric Cancer
AstraZeneca
Phase 2
163
Edinburgh, Leeds, London, Oxford
2023-01-16
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Aberdeen, Cambridge, Cardiff, Cheltenham, Edinburgh, London, Manchester, Middlesbrough
2022-12-29
Active, closed
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585Breast Cancer
AstraZeneca
Phase 3
1,174
Cambridge, Cardiff, Edinburgh, Greater London, London, Londonderry, Manchester, Newcastle upon Tyne
2022-11-28
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
AstraZeneca
Phase 3
644
Bristol, Cardiff, Edinburgh, London, Northampton, Nottingham, Warwick
2022-05-16
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
AstraZeneca
Phase 3
1,035
Edinburgh, Glasgow, Guildford, Hackensack, London, Manchester, Southampton, Sutton
2022-03-25
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
791
Birmingham, Brighton, Cardiff, Cheltenham, Edinburgh, High Heaton/Newcastle Upon Tyn, Leeds, London
2022-02-18
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
1,051
Belfast, Bristol, Dundee, Edinburgh, London, Middlesbrough, Poole, Torquay
2022-02-07
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
AstraZeneca
Phase 3
732
Blackpool, Bristol, Cardiff, Colchester, Edinburgh, London, Manchester, Nottingham
2021-10-18
Active, closed
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
NCT04739761Breast Cancer
AstraZeneca
Phase 3
506
Edinburgh
2021-06-22
Active, closed
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715Breast Cancer; HER2-positive; Metastatic
AstraZeneca
Phase 3
1,157
Edinburgh, Guildford, London, Manchester, Swansea, Taunton
2021-04-26
Active, closed
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963Ovarian Cancer, Breast Cancer
AstraZeneca
Phase 3
185
Birmingham, Edinburgh, Glasgow, Hull, London, Manchester, Taunton
2020-08-04
Rows per page Showing 1–25 of 34
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/edinburgh

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.